전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
median
medián
마지막 업데이트: 2017-04-26
사용 빈도: 19
품질:
efs (median)
efs (medián)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the median psa in the study at baseline was:
medián východiskovej hodnoty psa v štúdii bol nasledovný
마지막 업데이트: 2012-04-12
사용 빈도: 1
품질:
baseline (median)
východis- ková hodnota (medián)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
(median) (median)
zmena oproti
마지막 업데이트: 2012-04-12
사용 빈도: 2
품질:
the median duration of treatment in this study was 3.5 days.
priemerné trvanie liečby v tejto štúdii bolo 3,5 dňa.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
(median, u/l x day) free hemoglobin at end of study
(medián, u/ l x deň) voľný hemoglobín na konci
마지막 업데이트: 2012-04-12
사용 빈도: 2
품질:
patients received a median of 6 cycles of treatment in both study arms.
pacienti dostávali medián 6 cyklov liečby v oboch ramenách štúdie.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
these studies show that the median
Účinnosť zonegranu bola preukázaná v 4 dvojito zaslepených, placebom kontrolovaných štúdiách s trvaním do 24 týždňov a dávkovaním buď jeden alebo dvakrát denne.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
patients had a median platelet count of 14 x 109/l at study entry.
pri vstupe do štúdie mali pacienti medián počtu krvných doštičiek 14 x 109/l.
마지막 업데이트: 2017-04-26
사용 빈도: 6
품질:
the median age in the multicentre study was 40 years (age range 5 to 73).
medián veku v multicentrickej štúdii bol 40 rokov (vekový rozsah od 5 po 73).
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
the median time on study therapy was 181 weeks; 16% of patients discontinued before week
priemerný čas skúšanej liečby bol 181 týždňov; 16 % pacientov prerušilo liečbu pred 48. týždňom.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
the median age in the single centre study was 33 years (age range 9 to 75).
medián veku v štúdii s jedným centrom bol 33 rokov (vekový rozsah od 9 po 75).
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
the median cumulative rai activity administered prior to study entry was 350 mci (12.95 gbq).
medián kumulatívnej aktivity rádiojódu, ktorý bol podaný pred vstupom do štúdie bol 350 mci (12,95 gbq).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the median duration of therapy in study b2225 was 6.2months, with a maximum duration of 24.3months.
medián trvania liečby v klinickom skúšaní b2225 bol 6,2 mesiacov, maximálne trvanie 24,3 mesiacov.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the median age of patients enrolled in the study was 11.6 years (range 0.5 to 20.1 years).
medián veku pacientov zaradených do tejto štúdie bol 11,6 roka (rozsah od 0,5 do 20,1 roka).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
free haemoglobin at end of study (median, mg/dl)
voľný hemoglobín na konci štúdie (medián, mg/dl)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
ldh auc at end of study (median, u/l x day)
ldh auc na konci štúdie (medián, u/l x deň)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
patients in the study had received a median of 4 prior lines of therapy.
medián predchádzajúcich línií liečby bol 4.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in the future 1 study, the median exposure to study treatment was 13.1 weeks (range: 8.4 to 21.1).
v štúdii future 1 bol medián expozície hodnotenej liečby 13,1 týždňa (rozpätie 8,4 až 21,1).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: